Since most B-CLL at diagnosis are p53wild-type [17,18], a condition also characterizing the primary B-CLL samples analyzed in this study, it is noteworthy that previous studies on solid tumors have implicated the p53 pathway in mediating the anti-tumoral activity of DCA [5,6,19]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.